CAR T drives acute myeloid leukemia into submission in pre-clinical studies
Investigators have devised a novel method for improving CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumor-killing effect of a CAR T directed against acute myeloid leukemia.
Materials provided by Massachusetts General Hospital. Note: Content may be edited for style and length.
Source link aaaaa